Fischer Medical Ventures Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures submitted unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. On a consolidated basis, revenue from operations came in at Rs 1,152.83 lakhs, a sharp sequential drop from Rs 2,344.47 lakhs in the previous quarter, while profit after tax stood at Rs 40.28 lakhs (vs Rs 500.82 lakhs for the full year ended March 2025). On a standalone basis, the company swung to a loss of Rs 60.94 lakhs compared to a profit of Rs 83.94 lakhs in Q1 FY25, with revenue of Rs 454.23 lakhs. Auditor Bilimoria Mehta & Co. issued an unmodified (clean) review opinion on both sets of results. The board also fixed the 32nd AGM for September 29, 2025, appointed a scrutinizer and recommended a secretarial auditor, and noted the resignation of Independent Director Dr. Jacob Thomas due to personal reasons.
Mixed picture for shareholders: consolidated profitability is maintained but sequential revenues nearly halved, and standalone operations turned loss-making, which may weigh on near-term sentiment. The director resignation and other items are routine corporate housekeeping.